Boehringer/Lilly's Jardiance Wows With CVOT Data
This article was originally published in Scrip
Executive Summary
"Wonderful" and "profound" were just two of the adjectives thrown around at Sept. 17's symposium presentation of Boehringer Ingelheim and Eli Lilly & Co.'s EMPA-REG OUTCOMES study, the cardiovascular outcomes trial for their type 2 diabetes therapy Jardiance (empagliflozin), at the European Association for the Study of Diabetes.